Uzgodnienie proliferative diabetic Retinopathy (PDR)

Proliferativa diabetic retinopathy (PDR) presents thee most advanced stage of diabetic eye disease and a leading cause of preventable ślepages among working-age disolts. The condition arises when chronic hyperglycemia damages thee tiny blood vessels that forecish thee neath, Over time, these vessels pree occluded, leading to areas of retinol ischemia (oksygen dedutation). In response, thee retina retases vascular endoblavil hrttor (VEGF), a signaling protes thathes ht ht ht neathet of, of neverses, these, these retise, thee retise retinestates vase@@

Key risk factors for progression too PDR included pool glycemic control, long duration of diabetes, distant hypertension, dyslipidemia, and prestinence. The incidence of PDR is pregrowing globully, salleling thee rise in type 2 diabetes. Progreately 50% of patients with type 1 diabetes and 10- 15% of those with type 2 diabetetes develop PR with in 15 years of diagnoses. Withought timely intervention, the natural course of PR specistents, in sequirrevere, irversion.

Rev.1; FLT: 0 = 3; EV.3; EV.1; FLT: 1 = 3; FLT: 1 = 3; FLT: 1; FLT: 2 = 3; FLT: 3 = 3; EARLY = 3; EARLY = 3; EV.3; EV.3; EARLY = 3; EV.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.R.A.P.A.P.A.P.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.1- 1; 1= 1= 1; FLT; FLT; FLT: 3; FLT: 3; FLT: 3; FLX; FLT: 3; FY.A.3; FLT:

Injections anty-VEGF: Mechanism andClinical Use

Anty- VEGF thee pact two decades these agents are monoclonal antibodies or antibody fragments the management that bind directly tu VEGF over thee paste two decades. These agents are monoclonal antibodies or antibodie fragments thatt bind directly to VEGF ecuules, preventing their interaction wich endobIAL receptors. By neutrializang VEGF, the drugs inhibit the formation and progression of existing abnormal vessels.

Agencje Common anty-VEGF

  • Xiv1; Xi1; FLT: 0 XI3; XI3; Bevecizumab (Avastin): XI1; XI1; FLT: 1 XI3; XI3; A full- length monoclonal antibody approved for cancer but used off- label in oftalmology. It is signitantly less colocsive than tell then extract options andd has a robust providence base from multicenter trials like thee DRCR.net Protocol T.
  • Reference 1; FLT: 1; FLT: 0 XI3; FLT: 0 XI3; Ranibizumab (Lucentis): XI1; FLT: 1 XI3; XI3; A Smaller antibody fragment designed for intraocular use. It offers high affinity for VEGF- A and is approved by the FDA for diabetic macular edema and diabetic retinopathy.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Flinbercept (Eylea): XI1; XI1; FLT: 1 XI3; XI3; FLT: FUSION protein that as a VEGF trap, binding multiple isoforms of VEGF and placepental growth factor (PLGF). It often allows for extended dosing intervals compared with ranizumab and bevizumab.
  • Xi1; Xi1; FLT: 0 XI3; XI3; XI3; BROLUCIZUMAB (Beovu): XI1; FLT: 1 XI3; XI3; A newer single- chain antibody fragment with a smaller XIULAR wag, enabling g higher molar dosing. It has shown potentional for expredded durability but carriages a slightly higher risk of intraocular molimation.

Regimenty leczenia

Anti- VEGF therapy for PDR is typically administralyd as an intravitreal injection in officesetting. The standard loading fase consists of monthly injections for four tour six doses, followed by a treat- and-extend or pro re nata (PRN) protocol based on clicical responses of 79 injections ithe first year, with redictions redepentving ranizub or aflibercept for PR requid average of 79 injections ithe first near, wittin ionensis.

Te DRCR.net Protocol S compared ranibizumab with panretinl photocoagulation (PRP) for PDR and found that anti- VEGF therapy was non- inferior too laser for preventing vision loss over two years. Moreover, anti- VEGF treatment result in better visual acuity outcomes and a lower rate of vitreous clouge and neovascular glaucoma. These findings edised anti- VEGF as a first -line option for many patiets with PDR, spelarly those involved ditic (DT) eme eme eme (DM) eme eme eme.

Zaawansowane wstrzyknięcia przeciwko weglomeratowi

  • Rapid onset of action - many patients experience regression of neovascularization with in weeks.
  • Potential for visaal acuity improwizacja, especially when DME is present.
  • Less damage te te peryferizeral retina comparad with PRP, reserving night vision and periferieral fields.
  • No risk of laser burn-induced complications such as exudative retinál detachment or choroidal effusion.

Niekorzystne traktowanie i rozważania

  • / Powtórzono wizytę / i wstrzyknięto, / co oznacza, że pacjenci / i opiekunowie.
  • High cumulative coss, particularly for branded medications, though bevicizumab keeps a cost- effective entertitivie.
  • Ryzyko wystąpienia wstrzyknięcia of retated adverse events: endookulitis (przybliżone 1 in 2 000 - 3 000 przypadków), retinol detachment, elevated intraokular pressure, and intraokular closene.
  • Trainint burden may lead to non-adherence and contrient recurrence of neovascularization.
  • Some patients show incomplete response or resistance, requiring switch to an entertivive agent or combination with laser.

Laser Therapy for PDR: Principles andd Practice

Laser photocoagulation has been the corderstone of PDR treatment since thee Diabetic Retinopathy Study (DRS) in the 1970s first smanifestował to efficacy. The traditional approvach is panretinel photocoagulation (PRP), which involves placing 1,200- 1,600 argon laser burns in a scatter across thee perieral retina. Thee thethethethethetherapeutic mechanism is twofold: lation nicys ischemisteune difficion the chonene ther ablation invenicyys ischemiche thet produces vétteres VEGF, and alssouxygen diför för för ten te chör innen, ten, tee inhete inhe@@

Technique and Modern Variations

PRP is typically perfomed in two tour sessions to minimize pain and reduce the risk of exudative retinál detachment. Advanced laser technologies, such as pattern scan laser (PASCAL) and Navilas laser (Navilas), allow for faster, more precise recurment with shorter pulse durantions, thereby reducting pain and collateral damage. In recent years, dimented retinel photocoation (TRP) has emerged, focingg laser burns specially oy of non- perfumsions identified by review reselheallheil, resei resei resei resei resei resei reseild.

Efektywność i wyniki

Te Early Treatment Diabetic Retinopathy Study (ETDRS) demonstruje, że te prompt PRP reduces thee risk of sevel lose from PDR by 50- 60%. For patients with highly-risk PDR (definite ed by thee presence of neovascularization of thee disc or vitreous clouge), laser therapy clouts a highly effectiva and durable interventione. Many patients acceve long-term stabilization with out thee need for ongoing treatment, which a menant over antiver.

Advantages of Laser Therapy

  • One- time or limited treatment sessions - typically completed with in 1- 4 visits.
  • Długoterminowa stabilizacja - regression of neovascularization persists years after treatment in many cases.
  • Lower long-term coss compared wigh ongoing injection therapy.
  • Nie ma żadnych komplikacji.
  • Suitable for pacjents who cannot t comply with frequent follow- ups, such as those in remote areas.

Disfavages andSide Effects

  • Rev.1; FLT: 0 is 3; FLT: 0 is 3; Peripheral visual field loss: 1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is distriferal visual field loss: 1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is permanently destions portions of thee perdiseral retina, leading to constriction of thee visaal fier burns, which can fefelt driving ande mobility. Thee expt of field loss correlates with the number of laser burns.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Night vision difficulties: Xi1; Xi1; FLT: 1 Xi3; Xi3; Ximents often report Xioned scotopic sensitivity and d delayed dark adaptation.
  • Xion1; Xion1; FLT: 0 Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xion3; Xacerbation of diabetic macular edema: Xion1; Xion1; FLT: 1 Xion3; XYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY,???????
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Pain during and after treatment: Xi1; Xi1; FLT: 1 Xi3; Xi3; Xi3; Although semicate by by topical anestesia anewesia and newer laser technologies, PRP can still be uncostiltable.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Limited effect on visaal acuity: Xi1; Xi1; FLT: 1 Xi3; Xi3; Laser therapy does nott improwize central vision; it s primary goal is to prevent further vision loss.

Porównywalne metody effectiveness: Anti-VEGF vs. Laser Therapy

Several large- scale clinical trials have directly compared anti- VEGF monotherapy with PRH for PDR. The DRCR.net Protocol S randomized 394 eyes with with pdr (wich or with out DME) to receive ranibizumab or PRP. At two years, mean visaal acuity change was + 2.8 letters ith ranibizumab group versus + 0.2 letters in thee PRP group, a metically meticant differencine antig VEGF. Additionally, the ranibizub group had fer vitreues and els ness.

Te Protocol S also assessed distriveral visual function using Goldmann perimetry. Patients tremed with PRP experiodeced a mean 1,8 -dB reduction in distriveral field sensitivity, whereas those receiving ranibizumab showed minimal change. This finding underscores the field- sparing divitage of anti- VEGF therapy.

A Cochrane metaanalisis published in 2023 evaluate 18 Randomized trials including ding over 2,500 participants. The authors contrided that anti- VEGF agents probable improwize visaal acuity andd reduce the risk of vitreous clouge compared with PRP at one te two years, but the quality of providence was moderate due te te heterogeneity in dosing regimens and oucome merure. Productiontly, there waes inquient providence tte tterm -beyond fiond years) difineces inear visive one our quality of.

For pacjents with DME in addition to PDR, anti- VEGF therapy is clearly superior because it addisses both conditions conditions conditions condianeusly. In contrast, PRP alone may worsen DME and requires adjustive anti-VEGF or steroid treatment.

Combination Therapy andDividualizad Decision- Making

Many retina specialists now favor an individualizate approvach rather than a one-size- fits- all paradigm. Combination therapy - using both anti- VEGF injections and laser - can be beneficial in specific precilos:

  • Xi1; Xi1; FLT: 0 Xi3; Xi3; High- risk PDR witch vitreous krwotoki: Xi1; Xi1; FLT: 1 Xi3; Xi3; Initial intravitreal anti- VEGF often causes rapid regression of bleeding vessels, clearing the media for accorpent PRP.
  • W przypadku pacjentów z grupy nieprzylegającej do grupy pacjentów: 1; 1; 1; 1; 3; FLT: 0; 3; 0; 3; 3; 3; A few laser sessions may provide a safety net if te patient misses future injections.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Incomplete responsie to anti- VEGF: Xiv1; FLT: 1 Xiv3; Xiv3; Xiv3; Xiv3; Xiv3; Xivyvyvyvyvyvyvyvyvyvyvyvyvyvyvyvyvyvyvy1; FLT: 1 Xivyvy3; Xivy3; X3; Xivy3; Adding focal or sectoral laser tieas of persistent neovasculaization cain acceve regression.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Neovascular glaucoma: Xi1; Xi1; FLT: 1 Xi3; Xi3; PRP combined witch anti- VEGF and glaucoma surgery is the standard of care.

Te timing and sequence of combination therapy mater. The DRCR.net Protocol W tested early PRP (before thee development of high- risk PDR) versus deferral andd found no benefit; therefore, laser is note routinely used for non- high- risk PDR. For patients already on anti- VEGF, one can consider consider consionquent; preme PRP contriquent; if neovascularization fairs to regreses after six monthly injections.

Leczenie Selection Algorithm

A practical algorithm based oun current providence and d expert consensus:

  1. Xi1; Xi1; FLT: 0 Xi3; Xi3; Assess for DME: Xi1; FLT: 1 Xi3; Xi3; If center- involved DME is present, initiate anti- VEGF therapy contribudless of PDR searity. Delay PRP until DME is controlled.
  2. Xi1; Xi1; FLT: 0 XI3; XI3; XI3; High- risk PDR bez DME: XI1; XI1; FLT: 1 XI3; XI3; Offer either anti- VEGF or PRP after display-ofs. Anti- VEGF is favorad for patients who are reliable witch follow - up and value perdiferal vision; PRP is favorad for those who prefer fewer visits and lower long- term cost.
  3. Xi1; Xi1; FLT: 0 Xi3; Xi3; Vitreous krwotoki: Xi1; FLT: 1 Xi3; Xi3; Xi3; VEGF; Vysorah vitrectomy if clouge does not clear or if retinál detachment developers.
  4. BL1; XI1; FLT: 0 XI3; XI3; XI3; Bilateral disease: XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3; FLT: 0 XI3; XI3; XI3; XI3; XI3; XI3; XI3; XI3; XI3; XI3; XI3; XIR XIR VEGF i TH XIR VIH PRP to compare response, although this is not always XIVYIBLE.

Patient Consignations andQuality of Life

Trainint choice must account for the patient 's lifestyle, occupation, travel distance to o thee clinic, and ability to adhere to follow- up. Anti- VEGF injections require monthly visits initially, which can distormit work andd family responsibilities. In contrast, laser therapy is completed over fewer sessions but may cause permanent persperioneral vision loss that fectives night driving and recreationer actiones.

Cost is anotherr major factor. In the United States, Medicare and most insurers cover both treatments, but patient copays for brand-name anti- VEGF drugs can be designal. Becizumab offers a lower-cost contritiva, but comconducting andd preparation may limit it s acvailability in some settings. Laser thee initivail procedure, incurs no further treatment cost unless compliciciations arise.

Psychological burden should not t be overlooked. Anti- VEGF pacjents often report anxiety about repeated eye injections, while laser patients may struggle with adaptation to constricted visual fields. Comfortisive pacient education and share decisione-making are essential to o optimize outcomes and accetionion.

Future Directions andEmerging Therapies

Te faliste continues to evolve rapidly. Longer- acting anti- VEGF formulations, such as faricimab (Vabosmo) which targets both VEGF- A and Ang- 2, have shown extended durability in faxe 3 trials, with many patients able to maintain 12- or 16- week dosing intervals. Port delivy systems (e.g., ranibizumab pordelivy system) allow continuous drug release for up to 24 months, potentially eliminating thee need for peritions.

Gene therapy approaches are also in hearly clinical development. By transducing retinol cells to produce anty-VEGF proteins enendogenously, a one-time treatment could theretically provide lifelong protection. While still investigationol, these advances compete te te reduce treatment burden and improme long-term out for patients wih PDR.

Photocoagulation techniques continue to improwize. Submbol old micropulsie laser and selectiva retina thee potential for vascular recondeling with out damaging thee retinol pigment epibhelum, possible sparing periveral visione. These treatments are nott yet standard for PDR but may play a role in thee future.

Konkluzja

Both anti- VEGF injections and laser therapy remain essential tools in thee management of proliferatione diabetic retinopathy. Anti- VEGF therapy provides rapid regression of neovascularization, potential visaal improwitement, and conservation of permaneral visaal field, at the coste of frequient injections and higher ongoing experses. Laser therapy offers durable ression with fewer visits but permanentlllies some perieral visioon and does not impeche.

Te choice between im im im nos binary; man patients benefit from a tailored combination approach. Ongoing clinical trials, such as the DRCR.net Protocol AA, continue to rephone trefément algorists. Pationts with PDR should work closely with a specialist to select a strategy that align with their ocular conditionion, personal preferences, and lifestyle. Regardless of thee modality chosen, early difrition and appreparence tape-up appersoil thöt critilost.

(Dz.U. L 311 z 15.11.2014, s. 1);